A clinical trial of Neo Sampoon vaginal contraceptive tablets.
Results are reported of a clinical trial of Neo Sampoon vaginal contraceptive tablets, conducted by the International Fertility Research Program (IFRP) in collaboration with the Dacca Medical College Hospital, Bangladesh. Of the 150 women enrolled, 115 remained in the study at the end of 12 months. The 12-month cumulative gross life-table rates per 100 women were 6.5 for pregnancy and 24.8 for discontinuation due to other reasons. Discomfort associated with the heart generated by the tablets' effervescence was the primary side effect of Neo Sampoon use, and was one of the major causes of discontinuation. Regularity of use and acceptability of this foaming tablet appeared to be high compared to other barrier methods. Further research is needed on Neo Sampoon and other vaginal contraceptives to develop and promote methods that can help meet the worldwide demand for fertility control.
D000206:Actuarial Analysis; D000328:Adult; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral / Q000494:pharmacology; D005260:Female; D006801:Humans; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000494:pharmacology*; D011247:Pregnancy; D013607:Tablets; D014245:Trichomonas Infections / Q000209:etiology; D002579:Uterine Cervical Erosion / Q000209:etiology; D014621:Vagina
D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D013607:Tablets; D011092:Polyethylene Glycols; C029270:menfegol